A month has gone by since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have lost about 16.5% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks ...

Recursion (Nasdaq: RXRX) said on Wednesday that it had named Vicki Goodman as chief medical officer, effective April 6, 2026, succeeding David Mauro. Goodman had more than two decades of experience in ...

Altitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered by the National Institutes of Health. Accepted applicants will be admitted ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a next-gen biopharma company combining automated, experimental biology with artificial intelligence to discover and develop drugs at scale, today announced ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Recursion Pharmaceuticals has three different business segments that could grow. Its drug development pipeline will take the longest to yield sales. It'll need to scale up its collaborations and its ...